The CardioMEMS HF system. [Image courtesy of Abbott]

CardioMEMS HF系统。[图片由雅培提供]

An

安

Abbott

雅培

(NYSE: ABT)

（NYSE:ABT）

+

+

official said on social media that the company secured a significant Medicare win for its CardioMEMS platform.

这位官员在社交媒体上表示，该公司的CardioMEMS平台获得了重大的医疗保险胜利。

Keith Boettiger, President, Abbott Heart Failure, posted the update on LinkedIn. He said CMS granted a new national coverage determination for CardioMEMS.

。他说，CMS授予了CardioMEMS新的全国覆盖范围。

“This decision is a massive step forward toward increasing access to CardioMEMS to millions of heart failure patients,” Boettiger wrote.

Boettiger写道：“这一决定是朝着增加数百万心力衰竭患者使用CardioMEMS迈出的重要一步。”。

Remote monitoring technologies like the Abbott CardioMEMS sensor enable better management of heart failure. The CardioMEMS sensor’s design enables it to help people and their physicians proactively manage heart failure. It also helps to potentially prevent events that could lead to hospitalization.

像雅培CardioMEMS传感器这样的远程监测技术可以更好地管理心力衰竭。CardioMEMS传感器的设计使其能够帮助人们及其医生主动管理心力衰竭。它还有助于潜在地预防可能导致住院的事件。

CardioMEMS is implanted into the pulmonary artery via a minimally invasive procedure. The paperclip-sized sensor wirelessly transmits data about heart rates and pressures to the patient’s physicians. This continuous data stream aids in adjusting treatment plans and keeping hospital admissions at bay..

CardioMEMS通过微创手术植入肺动脉。回形针大小的传感器将心率和压力的数据无线传输给患者的医生。这种连续的数据流有助于调整治疗计划并阻止住院。。

CMS’ decision says the coverage focuses on the clinical indications for implantable pressure sensors for heart failure management. Boettiger said the decision represents a “testament to the work Abbott has done for years” to develop pulmonary pressure monitoring technology.

CMS的决定说，报道重点是用于心力衰竭管理的植入式压力传感器的临床适应症。Boettiger表示，这一决定“证明了雅培多年来在开发肺动脉压监测技术方面所做的工作”。

“CardioMEMS has been shown to improve quality of life while reducing re-hospitalization and mortality for NYHA class II and III heart failure patients, and we’re thrilled that as of today, more patients than ever before will have access to this critical device,” he wrote. “We’re grateful to the clinical providers, patients and advocates who have been alongside us on this journey.

他写道：“CardioMEMS已被证明可以改善生活质量，同时降低NYHA II级和III级心力衰竭患者的再住院率和死亡率，我们很高兴到今天，比以往任何时候都更多的患者可以使用这种关键设备。”。“我们感谢与我们同行的临床提供者、患者和倡导者。

Our work isn’t done – there are still far too many patients who lack coverage for CardioMEMS – but this is a critical step toward helping more people living with heart failure survive and thrive.”.

我们的工作还没有完成-仍然有太多的患者缺乏CardioMEMS的覆盖范围-但这是帮助更多心力衰竭患者生存和茁壮成长的关键一步。”。